Maravai LifeSciences Holdings Inc (MRVI) concluded trading on Wednesday at a closing price of $2.21, with 5.18 million shares of worth about $11.45 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.41% during that period and on April 03, 2025 the price saw a gain of about 2.31%. Currently the company’s common shares owned by public are about 141.98M shares, out of which, 116.77M shares are available for trading.
Stock saw a price change of -6.75% in past 5 days and over the past one month there was a price change of -22.18%. Year-to-date (YTD), MRVI shares are showing a performance of -59.45% which decreased to -74.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.07 but also hit the highest price of $11.56 during that period. The average intraday trading volume for Maravai LifeSciences Holdings Inc shares is 3.27 million. The stock is currently trading -10.03% below its 20-day simple moving average (SMA20), while that difference is down -38.16% for SMA50 and it goes to -65.40% lower than SMA200.
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) currently have 141.98M outstanding shares and institutions hold larger chunk of about 85.71% of that.
The stock has a current market capitalization of $562.09M and its 3Y-monthly beta is at 0.18. It has posted earnings per share of -$1.03 in the same period. It has Quick Ratio of 6.65 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRVI, volatility over the week remained 6.15% while standing at 8.77% over the month.
Stock’s fiscal year EPS is expected to drop by -154.72% while it is estimated to increase by 25.45% in next year. EPS is likely to grow at an annualized rate of 6.93% for next 5-years, compared to annual growth of -64.27% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on February 26, 2025 offering a Neutral rating for the stock and assigned a target price range of between $9 and $3 to it. Stock get a Mkt perform rating from William Blair on November 08, 2024.
